Advertisement
"The issuance of this patent supports our investment in AMRIX and itsinnovative technology, which offers the only once-daily treatment option forpatients suffering from acute muscle spasms," said Frank Baldino, Jr., Ph.D.,Chairman and Chief Executive Officer. "Physician and patient response toAMRIX has resulted in strong prescription growth in 2008 and we expect thatthis product will be a key growth driver in our business for many years."
Advertisement
About Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceuticalcompany dedicated to the discovery, development and commercialization ofinnovative products in four core therapeutic areas: central nervous system,pain, oncology and addiction. A member of the Fortune 1000, Cephaloncurrently employs approximately 3,000 people in the United States and Europe.U.S. sites include the company's headquarters in Frazer, Pennsylvania, andoffices, laboratories or manufacturing facilities in West Chester,Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Thecompany's European headquarters are located in Maisons-Alfort, France.
The company's proprietary products in the United States include:TREANDA(R) (bendamustine hydrochloride) for injection, AMRIX, PROVIGIL(R)(modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II],TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone forextended-release injectable suspension), GABITRIL(R) (tiagabinehydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oraltransmucosal fentanyl citrate) [C-II]. The company also markets numerousproducts internationally. Full prescribing information on its U.S. productsis available at http://www.cephalon.com or by calling 1-800-896-5855.
In addition to historical facts or statements of current condition, thispress release may contain forward-looking statements. Forward-lookingstatements provide Cephalon's current expectations or forecasts of futureevents. These may include statements regarding anticipated scientific progresson its research programs; development of potential pharmaceutical products;interpretation of clinical results; manufacturing development andcapabilities; market prospects for its products, including AMRIX; sales andearnings guidance; and other statements regarding matters that are nothistorical facts, including statements regarding the AMRIX patent. You mayidentify some of these forward-looking statements by the use of words in thestatements such as "anticipate," "estimate," "expect," "project," "intend,""plan," "believe" or other words and terms of similar meaning. Cephalon'sperformance and financial results could differ materially from those reflectedin these forward-looking statements due to general financial, economic,regulatory and political conditions affecting the biotechnology andpharmaceutical industries as well as more specific risks and uncertaintiesfacing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and10-K filed with the U.S. Securities and Exchange Commission. Given these risksand uncertainties, any or all of these forward-looking state
